- Home
- AXDX
as 05-14-2025 4:00pm EST
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
Upcoming Earnings Alert:
Get ready for potential market movements as Accelerate Diagnostics Inc. AXDX prepares to release earnings report on 20 May 2025.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | TUCSON |
| Market Cap: | 13.7M | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $2.09 | Next Earning Date: | 05-20-2025 |
| Revenue: | $11,698,000 | Revenue Growth: | -2.99% |
| Revenue Growth (this year): | 7.25% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Accelerate Diagnostics Inc. (AXDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Phillips Jack | AXDX | Chief Executive Officer | Apr 4 '25 | Sell | $0.65 | 25,343 | $16,472.95 | 191,374 | |
| Mertz Larry Michael | AXDX | Chief Technology Officer | Apr 4 '25 | Sell | $0.65 | 1,523 | $989.95 | 84,803 | |
| Patience David | AXDX | Chief Financial Officer | Apr 1 '25 | Sell | $0.71 | 6,816 | $4,839.36 | 64,568 | |
| Patience David | AXDX | Chief Financial Officer | Feb 26 '25 | Sell | $1.09 | 535 | $583.15 | 64,568 |
Latest Accelerate Diagnostics Inc. News
AXDX Breaking Stock News: Dive into AXDX Ticker-Specific Updates for Smart Investing
PR Newswire
7 days ago
Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
PR Newswire
2 months ago
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
PR Newswire
2 months ago
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results
PR Newswire
4 months ago
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results
Thomson Reuters StreetEvents
6 months ago
Q3 2024 Accelerate Diagnostics Inc Earnings Call
GuruFocus.com
6 months ago
Accelerate Diagnostics Inc (AXDX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
Zacks
6 months ago
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
6 months ago
Accelerate Diagnostics: Q3 Earnings Snapshot
Compare AXDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AXDX Accelerate Diagnostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.